A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Inclusion Criteria

• •1. Male or female participant aged 18 years or older.
• •2. Pathologic diagnosis of solid tumor malignancy that is locally advanced or metastatic at time of screening:
• •Part 1:
• •1. Combination therapy arms: Selected sarcoma indications from the following 2 separate categories.
• •* Soft tissue sarcoma: leiomyosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma (UPS; covering malignant fibrous histiocytoma) and synovial sarcoma.
• •* Bone sarcoma: Ewing's sarcoma (including extraskeletal), osteosarcoma, and chondrosarcoma.
• •2. Monotherapy arms:
• •* Sarcoma indications (including those listed for combination therapy arms) regardless of AXL gene amplification status.
• •* NSCLC regardless of AXL gene amplification status.
• •* Solid tumors (lymphomas participants are excluded) with known AXL gene amplification.
• •Part 2:
• •1. Combination therapy arms: Sarcoma indications and PAAD.
• •2. Monotherapy arms: PAAD, NSCLC and solid tumors with AXL expression.
• •3. Participants who are refractory to or intolerant to available standard therapy(ies) known to provide clinical benefit for their condition per Investigator judgment.
• •4. Participants with measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
• •5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
• •6. PAAD only: Royal Marsden Hospital Prognostic Score 0 - 1.